<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00274716</url>
  </required_header>
  <id_info>
    <org_study_id>0736-003</org_study_id>
    <secondary_id>2006_004</secondary_id>
    <nct_id>NCT00274716</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of MK0736 &amp; MK0916 in Patients With Hypertension (High Blood Pressure)(0736-003)(COMPLETED)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of MK0736 and MK0916 in Hypertensive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of two investigational
      drugs (MK-0736 and MK-0916) in lowering blood pressure and body weight in patients with
      hypertension (high blood pressure).

      This is an early phase trial and some specific protocol information is proprietary and not
      publicly available at this time. (Full information is available to trial participants).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants enrolled in the study will be separated into 2 strata based on baseline body
      mass index (BMI) assessments prior to being randomly assigned to study treatment. Study will
      include a 24-week treatment period comprised of 2 phases, A and B, each of which will 12
      weeks in duration.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12 in Participants With Higher Body Mass Indices (BMI)</measure>
    <time_frame>Baseline and Week 12 (end of Phase A)</time_frame>
    <description>Sitting diastolic blood pressure measured in triplicate at baseline and after 12 weeks of study drug administration. Mean value of the 3 measurements at the 2 timepoints was recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Reported a Clinical Adverse Event</measure>
    <time_frame>24 weeks</time_frame>
    <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE. A clinical AE was an AE reported as a result of a clinical examination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Reported a Laboratory Adverse Event</measure>
    <time_frame>24 weeks</time_frame>
    <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Were Discontinued From Study Due to Clinical Adverse Event</measure>
    <time_frame>24 weeks</time_frame>
    <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE. A clinical AE was an AE reported as a result of a clinical examination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Were Discontinued From Study Due to Laboratory Adverse Event</measure>
    <time_frame>24 weeks</time_frame>
    <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 12 in Participants With Higher Body Mass Indices (BMI)</measure>
    <time_frame>Baseline and Week 12 (end of Phase A)</time_frame>
    <description>Sitting systolic blood pressure measured in triplicate at baseline and after 12 weeks of study drug administration. Mean trough value of the 3 measurements at the 2 timepoints was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight (kg) at Week 12 in Participants With Higher BMI</measure>
    <time_frame>Baseline and Week 12 (end of Phase A)</time_frame>
    <description>Weight was measured in duplicate (2 measurements) at baseline and after 12 weeks of study drug administration. The mean of the 2 values at each assessment was used in analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Waist Circumference at Week 12 in Participants With Higher BMI</measure>
    <time_frame>Baseline and Week 12 (end of Phase A)</time_frame>
    <description>Waist circumference measured in cm at baseline and after 12 weeks of study drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 in Participants With Higher Body Mass Indices (BMI)</measure>
    <time_frame>Baseline and Week 12 (end of Phase A)</time_frame>
    <description>LDL-C was calculated by the method of Friedewald equation at baseline and after 12 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline for High Density Lipoprotein Cholesterol (HDL-C) at Week 12 in Participants With Higher BMI</measure>
    <time_frame>Baseline and Week 12 (end of Phase A)</time_frame>
    <description>HDL-C measured at baseline and after 12 weeks of study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Triglycerides (TG) at Week 12 in Participants With Higher Body Mass Indices (BMI)</measure>
    <time_frame>Baseline and Week 12 (end of Phase A)</time_frame>
    <description>TG measured at baseline and after 12 weeks of study drug administration</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">249</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>High BMI:MK-0736 2mg→Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants administered MK-0736 2mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High BMI:MK-0736 7mg→Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants administered MK-0736 7mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High BMI:MK-0916 6mg→MK-0916 6mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High BMI:Placebo→Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low BMI:MK-0916 6mg→MK-0916 6mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low BMI:Placebo→Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0736</intervention_name>
    <arm_group_label>High BMI:MK-0736 2mg→Placebo</arm_group_label>
    <arm_group_label>High BMI:MK-0736 7mg→Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK0916</intervention_name>
    <arm_group_label>High BMI:MK-0916 6mg→MK-0916 6mg</arm_group_label>
    <arm_group_label>Low BMI:MK-0916 6mg→MK-0916 6mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>High BMI:MK-0736 2mg→Placebo</arm_group_label>
    <arm_group_label>High BMI:MK-0736 7mg→Placebo</arm_group_label>
    <arm_group_label>High BMI:Placebo→Placebo</arm_group_label>
    <arm_group_label>Low BMI:Placebo→Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hypertension systolic blood pressure (SBP) &lt;/= 160mm Hg and diastolic blood pressure
             (DBP): 90-105mm Hg

        Exclusion Criteria:

          -  Pre-menopausal women

          -  patients currently taking more than two (2) blood pressure lowering medications

          -  Body Mas Index (BMI)&gt;40 kg/m2 (morbidly obese patients)

          -  History of Alcohol abuse (&lt;3 Years)

          -  History of diabetes,chronic kidney disease, Active liver disease, recent heart attack
             or stroke
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>Puerto Rico</country>
    <country>South Africa</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2006</study_first_submitted>
  <study_first_submitted_qc>January 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2006</study_first_posted>
  <results_first_submitted>December 23, 2013</results_first_submitted>
  <results_first_submitted_qc>December 23, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 14, 2014</results_first_posted>
  <last_update_submitted>June 8, 2015</last_update_submitted>
  <last_update_submitted_qc>June 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Enrolled participants were divided into 2 strata: higher body mass index (BMI) (27 kg/m^2≤BMI&lt;41 kg/m^2) and lower BMI (20 kg/m^2≤BMI&lt;27 kg/m^2) prior to being randomly assigned study treatment. Data from High BMI groups were to be utilized in the primary and secondary analyses; data from low BMI groups were to be utilized in exploratory analyses.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>High BMI:MK-0736 2mg→Placebo</title>
          <description>Participants administered MK-0736 2mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)</description>
        </group>
        <group group_id="P2">
          <title>High BMI:MK-0736 7mg→Placebo</title>
          <description>Participants administered MK-0736 7mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)</description>
        </group>
        <group group_id="P3">
          <title>High BMI:MK-0916 6mg→MK-0916 6mg</title>
          <description>Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
        </group>
        <group group_id="P4">
          <title>High BMI:Placebo→Placebo</title>
          <description>Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
        </group>
        <group group_id="P5">
          <title>Low BMI:MK-0916 6mg→MK-0916 6mg</title>
          <description>Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
        </group>
        <group group_id="P6">
          <title>Low BMI:Placebo→Placebo</title>
          <description>Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Phase A</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="51"/>
                <participants group_id="P5" count="19"/>
                <participants group_id="P6" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="42"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other non-reported reason</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant moved</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Terminated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met criteria for discontinuation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Completed but did not enter Phase B</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase B</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="42"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="41"/>
                <participants group_id="P5" count="16"/>
                <participants group_id="P6" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant moved</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other non-reported reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>High BMI:MK-0736 2mg→Placebo</title>
          <description>Participants administered MK-0736 2mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)</description>
        </group>
        <group group_id="B2">
          <title>High BMI:MK-0736 7mg→Placebo</title>
          <description>Participants administered MK-0736 7mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)</description>
        </group>
        <group group_id="B3">
          <title>High BMI:MK-0916 6mg→MK-0916 6mg</title>
          <description>Participants who received MK-0916 6 mg in Phase A and continued on MK-0916 6 mg for 12 weeks in Phase B</description>
        </group>
        <group group_id="B4">
          <title>High BMI:Placebo→Placebo</title>
          <description>Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
        </group>
        <group group_id="B5">
          <title>Low BMI:MK-0916 6mg→MK-0916 6mg</title>
          <description>Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
        </group>
        <group group_id="B6">
          <title>Low BMI:Placebo→Placebo</title>
          <description>Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="52"/>
            <count group_id="B4" value="51"/>
            <count group_id="B5" value="19"/>
            <count group_id="B6" value="19"/>
            <count group_id="B7" value="249"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>21 to 30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>31 to 40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>41 to 50 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>51 to 60 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>61 to 70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;70 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12 in Participants With Higher Body Mass Indices (BMI)</title>
        <description>Sitting diastolic blood pressure measured in triplicate at baseline and after 12 weeks of study drug administration. Mean value of the 3 measurements at the 2 timepoints was recorded.</description>
        <time_frame>Baseline and Week 12 (end of Phase A)</time_frame>
        <population>Higher BMI participants in the All Patients Treated (APT) Population, which included all randomized participants who had valid efficacy measurements at baseline and at least once during the double-blind treatment period. The MK-0916 6.0 mg and Placebo Low BMI groups were not included in the planned analysis for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0736 2.0 mg High BMI</title>
            <description>Participants administered MK-0736 2.0 mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>MK-0736 7.0 mg High BMI</title>
            <description>Participants administered MK-0736 7.0 mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>MK-0916 6.0 mg High BMI</title>
            <description>Participants administered MK-0916 6.0 mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo High BMI</title>
            <description>Participants administered placebo tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Sitting Diastolic Blood Pressure (SiDBP) at Week 12 in Participants With Higher Body Mass Indices (BMI)</title>
          <description>Sitting diastolic blood pressure measured in triplicate at baseline and after 12 weeks of study drug administration. Mean value of the 3 measurements at the 2 timepoints was recorded.</description>
          <population>Higher BMI participants in the All Patients Treated (APT) Population, which included all randomized participants who had valid efficacy measurements at baseline and at least once during the double-blind treatment period. The MK-0916 6.0 mg and Placebo Low BMI groups were not included in the planned analysis for this endpoint.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2" spread="7.3"/>
                    <measurement group_id="O2" value="-2.4" spread="8.1"/>
                    <measurement group_id="O3" value="-3.1" spread="7.9"/>
                    <measurement group_id="O4" value="-0.2" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.157</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline mean trough SiDBP as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.3</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline mean trough SiDBP as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.1</ci_lower_limit>
            <ci_upper_limit>-1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.042</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline mean trough SiDBP as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.4</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.517</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline mean trough SiDBP as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.602</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline mean trough SiDBP as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>2.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 12 in Participants With Higher Body Mass Indices (BMI)</title>
        <description>Sitting systolic blood pressure measured in triplicate at baseline and after 12 weeks of study drug administration. Mean trough value of the 3 measurements at the 2 timepoints was recorded.</description>
        <time_frame>Baseline and Week 12 (end of Phase A)</time_frame>
        <population>Higher BMI participants in the All Patients Treated (APT) Population, which included all randomized participants who had valid efficacy measurements at baseline and at least once during the double-blind treatment period. The MK-0916 6.0 mg and Placebo Low BMI groups were not included in the planned analysis for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0736 2.0 mg High BMI</title>
            <description>Participants administered MK-0736 2.0 mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>MK-0736 7.0 mg High BMI</title>
            <description>Participants administered MK-0736 7.0 mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>MK-0916 6.0 mg High BMI</title>
            <description>Participants administered MK-0916 6.0 mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo High BMI</title>
            <description>Participants administered placebo tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Trough Sitting Systolic Blood Pressure (SiSBP) at Week 12 in Participants With Higher Body Mass Indices (BMI)</title>
          <description>Sitting systolic blood pressure measured in triplicate at baseline and after 12 weeks of study drug administration. Mean trough value of the 3 measurements at the 2 timepoints was recorded.</description>
          <population>Higher BMI participants in the All Patients Treated (APT) Population, which included all randomized participants who had valid efficacy measurements at baseline and at least once during the double-blind treatment period. The MK-0916 6.0 mg and Placebo Low BMI groups were not included in the planned analysis for this endpoint.</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="13.2"/>
                    <measurement group_id="O2" value="-4.2" spread="12.9"/>
                    <measurement group_id="O3" value="-3.2" spread="11.3"/>
                    <measurement group_id="O4" value="0.7" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.046</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline mean trough SiDBP as a continuous variable</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-4.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.7</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.108</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline mean trough SiDBP as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.7</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.099</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline mean trough SiDBP as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.0</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.752</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline mean trough SiDBP as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.7</ci_lower_limit>
            <ci_upper_limit>4.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.941</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline mean trough SiDBP as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.7</ci_lower_limit>
            <ci_upper_limit>5.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight (kg) at Week 12 in Participants With Higher BMI</title>
        <description>Weight was measured in duplicate (2 measurements) at baseline and after 12 weeks of study drug administration. The mean of the 2 values at each assessment was used in analysis.</description>
        <time_frame>Baseline and Week 12 (end of Phase A)</time_frame>
        <population>Higher BMI participants in the All Patients Treated (APT) Population, which included all randomized participants who had valid efficacy measurements at baseline and at least once during the double-blind treatment period. The MK-0916 6.0 mg and Placebo Low BMI groups were not included in the planned analysis for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0736 2.0 mg High BMI</title>
            <description>Participants administered MK-0736 2.0 mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>MK-0736 7.0 mg High BMI</title>
            <description>Participants administered MK-0736 7.0 mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>MK-0916 6.0 mg High BMI</title>
            <description>Participants administered MK-0916 6.0 mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo High BMI</title>
            <description>Participants administered placebo tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight (kg) at Week 12 in Participants With Higher BMI</title>
          <description>Weight was measured in duplicate (2 measurements) at baseline and after 12 weeks of study drug administration. The mean of the 2 values at each assessment was used in analysis.</description>
          <population>Higher BMI participants in the All Patients Treated (APT) Population, which included all randomized participants who had valid efficacy measurements at baseline and at least once during the double-blind treatment period. The MK-0916 6.0 mg and Placebo Low BMI groups were not included in the planned analysis for this endpoint.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="1.8"/>
                    <measurement group_id="O2" value="-0.9" spread="2.0"/>
                    <measurement group_id="O3" value="-1.2" spread="1.8"/>
                    <measurement group_id="O4" value="0.5" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline weight as a continuous variable</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>-1.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>-0.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline weight as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.9</ci_lower_limit>
            <ci_upper_limit>-0.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline weight as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.7</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.4</ci_lower_limit>
            <ci_upper_limit>-1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.462</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline weight as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>1.0</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.118</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline weight as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2</ci_lower_limit>
            <ci_upper_limit>1.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Waist Circumference at Week 12 in Participants With Higher BMI</title>
        <description>Waist circumference measured in cm at baseline and after 12 weeks of study drug administration</description>
        <time_frame>Baseline and Week 12 (end of Phase A)</time_frame>
        <population>Higher BMI participants in the All Patients Treated (APT) Population, which included all randomized participants who had valid efficacy measurements at baseline and at least once during the double-blind treatment period. The MK-0916 6.0 mg and Placebo Low BMI groups were not included in the planned analysis for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0736 2.0 mg High BMI</title>
            <description>Participants administered MK-0736 2.0 mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>MK-0736 7.0 mg High BMI</title>
            <description>Participants administered MK-0736 7.0 mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>MK-0916 6.0 mg High BMI</title>
            <description>Participants administered MK-0916 6.0 mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo High BMI</title>
            <description>Participants administered placebo tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Waist Circumference at Week 12 in Participants With Higher BMI</title>
          <description>Waist circumference measured in cm at baseline and after 12 weeks of study drug administration</description>
          <population>Higher BMI participants in the All Patients Treated (APT) Population, which included all randomized participants who had valid efficacy measurements at baseline and at least once during the double-blind treatment period. The MK-0916 6.0 mg and Placebo Low BMI groups were not included in the planned analysis for this endpoint.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="49"/>
                <count group_id="O4" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="4.9"/>
                    <measurement group_id="O2" value="-0.9" spread="2.9"/>
                    <measurement group_id="O3" value="-0.3" spread="4.9"/>
                    <measurement group_id="O4" value="1.2" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.059</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline waist as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.7</ci_lower_limit>
            <ci_upper_limit>0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline waist as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.5</ci_lower_limit>
            <ci_upper_limit>-1.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.136</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline waist as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.3</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.686</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline waist as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.022</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline waist as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.2</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.0</ci_lower_limit>
            <ci_upper_limit>-0.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 in Participants With Higher Body Mass Indices (BMI)</title>
        <description>LDL-C was calculated by the method of Friedewald equation at baseline and after 12 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 12 (end of Phase A)</time_frame>
        <population>Higher BMI participants in the All Patients Treated (APT) Population, which included all randomized participants who had valid efficacy measurements at baseline and at least once during the double-blind treatment period. The MK-0916 6.0 mg and Placebo Low BMI groups were not included in the planned analysis for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0736 2.0 mg High BMI</title>
            <description>Participants administered MK-0736 2.0 mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>MK-0736 7.0 mg High BMI</title>
            <description>Participants administered MK-0736 7.0 mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>MK-0916 6.0 mg High BMI</title>
            <description>Participants administered MK-0916 6.0 mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo High BMI</title>
            <description>Participants administered placebo tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12 in Participants With Higher Body Mass Indices (BMI)</title>
          <description>LDL-C was calculated by the method of Friedewald equation at baseline and after 12 weeks of study drug administration.</description>
          <population>Higher BMI participants in the All Patients Treated (APT) Population, which included all randomized participants who had valid efficacy measurements at baseline and at least once during the double-blind treatment period. The MK-0916 6.0 mg and Placebo Low BMI groups were not included in the planned analysis for this endpoint.</population>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="44"/>
                <count group_id="O4" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="23.3"/>
                    <measurement group_id="O2" value="-5.2" spread="20.4"/>
                    <measurement group_id="O3" value="4.5" spread="23.0"/>
                    <measurement group_id="O4" value="5.7" spread="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline LDL-C as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-12.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.3</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.8</ci_lower_limit>
            <ci_upper_limit>-3.7</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.066</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline LDL-C as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.7</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.319</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline LDL-C as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.5</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.4</ci_lower_limit>
            <ci_upper_limit>4.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.077</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline LDL-C as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.4</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.418</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline LDL-C as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>4.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.2</ci_lower_limit>
            <ci_upper_limit>5.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline for High Density Lipoprotein Cholesterol (HDL-C) at Week 12 in Participants With Higher BMI</title>
        <description>HDL-C measured at baseline and after 12 weeks of study drug administration.</description>
        <time_frame>Baseline and Week 12 (end of Phase A)</time_frame>
        <population>Higher BMI participants in the All Patients Treated (APT) Population, which included all randomized participants who had valid efficacy measurements at baseline and at least once during the double-blind treatment period. The MK-0916 6.0 mg and Placebo Low BMI groups were not included in the planned analysis for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0736 2.0 mg High BMI</title>
            <description>Participants administered MK-0736 2.0 mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>MK-0736 7.0 mg High BMI</title>
            <description>Participants administered MK-0736 7.0 mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>MK-0916 6.0 mg High BMI</title>
            <description>Participants administered MK-0916 6.0 mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo High BMI</title>
            <description>Participants administered placebo tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline for High Density Lipoprotein Cholesterol (HDL-C) at Week 12 in Participants With Higher BMI</title>
          <description>HDL-C measured at baseline and after 12 weeks of study drug administration.</description>
          <population>Higher BMI participants in the All Patients Treated (APT) Population, which included all randomized participants who had valid efficacy measurements at baseline and at least once during the double-blind treatment period. The MK-0916 6.0 mg and Placebo Low BMI groups were not included in the planned analysis for this endpoint.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="5.7"/>
                    <measurement group_id="O2" value="-1.8" spread="6.7"/>
                    <measurement group_id="O3" value="1.6" spread="6.7"/>
                    <measurement group_id="O4" value="1.5" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline HDL-C as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.3</ci_lower_limit>
            <ci_upper_limit>-1.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.124</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline HDL-C as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.0</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.2</ci_lower_limit>
            <ci_upper_limit>1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.429</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline HDL-C as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.6</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.1</ci_lower_limit>
            <ci_upper_limit>7.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline HDL-C as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-8.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.3</ci_lower_limit>
            <ci_upper_limit>-3.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline HDL-C as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.5</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.1</ci_lower_limit>
            <ci_upper_limit>-1.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Triglycerides (TG) at Week 12 in Participants With Higher Body Mass Indices (BMI)</title>
        <description>TG measured at baseline and after 12 weeks of study drug administration</description>
        <time_frame>Baseline and Week 12 (end of Phase A)</time_frame>
        <population>Higher BMI participants in the All Patients Treated (APT) Population, which included all randomized participants who had valid efficacy measurements at baseline and at least once during the double-blind treatment period. The MK-0916 6.0 mg and Placebo Low BMI groups were not included in the planned analysis for this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0736 2.0 mg High BMI</title>
            <description>Participants administered MK-0736 2.0 mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>MK-0736 7.0 mg High BMI</title>
            <description>Participants administered MK-0736 7.0 mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>MK-0916 6.0 mg High BMI</title>
            <description>Participants administered MK-0916 6.0 mg tablet once daily for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Placebo High BMI</title>
            <description>Participants administered placebo tablet once daily for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Triglycerides (TG) at Week 12 in Participants With Higher Body Mass Indices (BMI)</title>
          <description>TG measured at baseline and after 12 weeks of study drug administration</description>
          <population>Higher BMI participants in the All Patients Treated (APT) Population, which included all randomized participants who had valid efficacy measurements at baseline and at least once during the double-blind treatment period. The MK-0916 6.0 mg and Placebo Low BMI groups were not included in the planned analysis for this endpoint.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="40.3"/>
                    <measurement group_id="O2" value="20.1" spread="54.9"/>
                    <measurement group_id="O3" value="11.6" spread="41.2"/>
                    <measurement group_id="O4" value="11.1" spread="40.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.587</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline TG as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>4.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.9</ci_lower_limit>
            <ci_upper_limit>22.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.562</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline TG as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.5</ci_lower_limit>
            <ci_upper_limit>12.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.802</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline TG as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>2.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.8</ci_lower_limit>
            <ci_upper_limit>20.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.772</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline TG as a continuous variable</method_desc>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>2.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.0</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.2</ci_lower_limit>
            <ci_upper_limit>20.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.409</p_value>
            <method>ANCOVA</method>
            <method_desc>Treatment group and ambulatory blood pressure measurement (ABPM; yes or no) as class variables and baseline TG as a continuous variable</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>9.2</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-25.9</ci_lower_limit>
            <ci_upper_limit>10.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Reported a Clinical Adverse Event</title>
        <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE. A clinical AE was an AE reported as a result of a clinical examination.</description>
        <time_frame>24 weeks</time_frame>
        <population>All Patients as Treated (ApaT) population, defined as all randomized participants who received at least 1 dose of double-blind study therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>High BMI:MK-0736 2mg→Placebo</title>
            <description>Participants administered MK-0736 2mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)</description>
          </group>
          <group group_id="O2">
            <title>High BMI:MK-0736 7mg→Placebo</title>
            <description>Participants administered MK-0736 7mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)</description>
          </group>
          <group group_id="O3">
            <title>High BMI:MK-0916 6mg→MK-0916 6mg</title>
            <description>Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
          </group>
          <group group_id="O4">
            <title>High BMI:Placebo→Placebo</title>
            <description>Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
          </group>
          <group group_id="O5">
            <title>Low BMI:MK-0916 6mg→MK-0916 6mg</title>
            <description>Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
          </group>
          <group group_id="O6">
            <title>Low BMI:Placebo→Placebo</title>
            <description>Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Reported a Clinical Adverse Event</title>
          <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE. A clinical AE was an AE reported as a result of a clinical examination.</description>
          <population>All Patients as Treated (ApaT) population, defined as all randomized participants who received at least 1 dose of double-blind study therapy.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="36"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Reported a Laboratory Adverse Event</title>
        <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test.</description>
        <time_frame>24 weeks</time_frame>
        <population>All Patients as Treated (ApaT) population, defined as all randomized participants who received at least 1 dose of double-blind study therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>High BMI:MK-0736 2mg→Placebo</title>
            <description>Participants administered MK-0736 2mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)</description>
          </group>
          <group group_id="O2">
            <title>High BMI:MK-0736 7mg→Placebo</title>
            <description>Participants administered MK-0736 7mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)</description>
          </group>
          <group group_id="O3">
            <title>High BMI:MK-0916 6mg→MK-0916 6mg</title>
            <description>Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
          </group>
          <group group_id="O4">
            <title>High BMI:Placebo→Placebo</title>
            <description>Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
          </group>
          <group group_id="O5">
            <title>Low BMI:MK-0916 6mg→MK-0916 6mg</title>
            <description>Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
          </group>
          <group group_id="O6">
            <title>Low BMI:Placebo→Placebo</title>
            <description>Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Reported a Laboratory Adverse Event</title>
          <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test.</description>
          <population>All Patients as Treated (ApaT) population, defined as all randomized participants who received at least 1 dose of double-blind study therapy.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Were Discontinued From Study Due to Clinical Adverse Event</title>
        <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE. A clinical AE was an AE reported as a result of a clinical examination.</description>
        <time_frame>24 weeks</time_frame>
        <population>All Patients as Treated (ApaT) population, defined as all randomized participants who received at least 1 dose of double-blind study therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>High BMI:MK-0736 2mg→Placebo</title>
            <description>Participants administered MK-0736 2mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)</description>
          </group>
          <group group_id="O2">
            <title>High BMI:MK-0736 7mg→Placebo</title>
            <description>Participants administered MK-0736 7mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)</description>
          </group>
          <group group_id="O3">
            <title>High BMI:MK-0916 6mg→MK-0916 6mg</title>
            <description>Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
          </group>
          <group group_id="O4">
            <title>High BMI:Placebo→Placebo</title>
            <description>Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
          </group>
          <group group_id="O5">
            <title>Low BMI:MK-0916 6mg→MK-0916 6mg</title>
            <description>Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
          </group>
          <group group_id="O6">
            <title>Low BMI:Placebo→Placebo</title>
            <description>Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were Discontinued From Study Due to Clinical Adverse Event</title>
          <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE. A clinical AE was an AE reported as a result of a clinical examination.</description>
          <population>All Patients as Treated (ApaT) population, defined as all randomized participants who received at least 1 dose of double-blind study therapy.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Were Discontinued From Study Due to Laboratory Adverse Event</title>
        <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test.</description>
        <time_frame>24 weeks</time_frame>
        <population>All Patients as Treated (ApaT) population, defined as all randomized participants who received at least 1 dose of double-blind study therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>High BMI:MK-0736 2mg→Placebo</title>
            <description>Participants administered MK-0736 2mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)</description>
          </group>
          <group group_id="O2">
            <title>High BMI:MK-0736 7mg→Placebo</title>
            <description>Participants administered MK-0736 7mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)</description>
          </group>
          <group group_id="O3">
            <title>High BMI:MK-0916 6mg→MK-0916 6mg</title>
            <description>Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
          </group>
          <group group_id="O4">
            <title>High BMI:Placebo→Placebo</title>
            <description>Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
          </group>
          <group group_id="O5">
            <title>Low BMI:MK-0916 6mg→MK-0916 6mg</title>
            <description>Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
          </group>
          <group group_id="O6">
            <title>Low BMI:Placebo→Placebo</title>
            <description>Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were Discontinued From Study Due to Laboratory Adverse Event</title>
          <description>An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which is temporally associated with the use of the SPONSOR'S product, is also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test.</description>
          <population>All Patients as Treated (ApaT) population, defined as all randomized participants who received at least 1 dose of double-blind study therapy.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="51"/>
                <count group_id="O5" value="19"/>
                <count group_id="O6" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>High BMI:MK-0736 2mg→Placebo</title>
          <description>Participants administered MK-0736 2mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)</description>
        </group>
        <group group_id="E2">
          <title>High BMI:MK-0736 7mg→Placebo</title>
          <description>Participants administered MK-0736 7mg tablet once daily for 12 weeks (Phase A) then administered placebo once daily for 12 weeks (Phase B)</description>
        </group>
        <group group_id="E3">
          <title>High BMI:MK-0916 6mg→MK-0916 6mg</title>
          <description>Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
        </group>
        <group group_id="E4">
          <title>High BMI:Placebo→Placebo</title>
          <description>Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
        </group>
        <group group_id="E5">
          <title>Low BMI:MK-0916 6mg→MK-0916 6mg</title>
          <description>Participants administered MK-0916 6mg tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
        </group>
        <group group_id="E6">
          <title>Low BMI:Placebo→Placebo</title>
          <description>Participants administered placebo tablet once daily in both Phase A (12 weeks) and Phase B (12 weeks)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Meningitis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Lichen Sclerosus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Change Of Bowel Habit</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lip Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Oral Herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Tooth Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Fluid Retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Flank Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Sinus Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Postmenopausal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Productive Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Rhinitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Sinus Congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Night Sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Hot Flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The SPONSOR must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the SPONSOR as confidential must be deleted prior to submission. SPONSOR review can be expedited to meet publication guidelines.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

